Lignans Extract from Knotwood of Norway Spruce-A Possible New Weapon against GTDs.

J Fungi (Basel)

Mendeleum-Institute of Genetics, Faculty of Horticulture, Mendel University in Brno, Valtická 334, 691 44 Lednice na Moravě, Czech Republic.

Published: March 2022

Grapevine trunk diseases (GTDs) pose a major threat to the wine industry worldwide. Currently, efficient biological methods or chemical compounds are not available for the treatment of infected grapevines. In the present study, we used an extract from the knotwood of spruce trees as a biological control against GTDs. Our in vitro trial was focused on the antifungal effects of the extract against the most common GTD pathogens-, , , , , , and . Our in vitro trial revealed a high antifungal effect of the extract against all tested fungi. The inhibition rates varied among the different species from 30% to 100% using 1 mg·mL extract. Subsequently, the efficiency of the extract was supported by an in planta experiment. Commercial grafts of were treated with the extract and planted. The total genomic DNA of grapevines was extracted 10 days and 180 days after the treatment. The fungal microbial diversities of the treated/untreated plants were compared using high-throughput amplicon sequencing (HTAS). Treated plants showed 76.9% lower relative abundance of the genus and 70% lower relative abundance of the genus 10 days after treatment. A similar scenario was observed for the genus 180 days after treatment, where treated plants showed 76% lower relative abundance of this genus compared with untreated grapevines.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025846PMC
http://dx.doi.org/10.3390/jof8040357DOI Listing

Publication Analysis

Top Keywords

days treatment
12
lower relative
12
relative abundance
12
abundance genus
12
extract knotwood
8
vitro trial
8
180 days
8
treated plants
8
extract
6
lignans extract
4

Similar Publications

Successful Management of Acetamiprid Intoxication in a Captive Eurasian Goshawk ().

J Avian Med Surg

January 2025

Ennetseeklinik für Kleintiere, Exotic Pet Department, 6331 Hünenberg, Zug, Switzerland.

A captive, 1-year-old, male Eurasian goshawk () weighing 0.85 kg and owned by a falconer was presented with a history of acute onset of weakness, dyspnea, diarrhea, and regurgitation of a fresh-thawed pigeon contaminated with acetamiprid, an insecticide used in the raptor enclosure. The raptor had eaten the contaminated pigeon approximately 10-12 hours earlier.

View Article and Find Full Text PDF

Ebola virus (EBOV) causes severe disease in humans, with mortality as high as 90%. The small-molecule antiviral drug remdesivir (RDV) has demonstrated a survival benefit in EBOV-exposed rhesus macaques. Here, we characterize the efficacy of multiple intravenous RDV dosing regimens on survival of rhesus macaques 42 days after intramuscular EBOV exposure.

View Article and Find Full Text PDF

Nasal spray treatments that inhibit the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) entry into nose and nasopharynx at early stages can be an appropriate approach to stop or delay the progression of the disease. We performed a prospective, randomized, double-blind, placebo-controlled, parallel-group, multicentric, phase II clinical trial comparing the rate of hospitalization due to COVID-19 infection between azelastine 0.1% nasal spray and placebo nasal spray treatment groups.

View Article and Find Full Text PDF

Pemphigus and Bullous Pemphigoid Following COVID-19 Vaccination: A Systematic Review.

Viruses

December 2024

Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, Italy.

The COVID-19 pandemic has encouraged the rapid development and licensing of vaccines against SARS-CoV-2. Currently, numerous vaccines are available on a global scale and are based on different mechanisms of action, including mRNA technology, viral vectors, inactive viruses, and subunit particles. Mass vaccination conducted worldwide has highlighted the potential development of side effects, including ones with skin involvement.

View Article and Find Full Text PDF

The Ebola virus (EBOV) causes severe disease in humans, and animal models are needed to evaluate the efficacy of vaccines and therapeutics. While non-human primate (NHP) and rodent EBOV infection models have been well characterized, there is a growing need for an intermediate model. Here, we provide the first report of a small-particle aerosol (AE) EBOV ferret model and disease progression compared with the intramuscular (IM) EBOV ferret model.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!